Identification and validation of novel human pregnane X receptor activators among prescribed drugs via ligand-based virtual screening

Drug Metabolism and Disposition

Volumn 39, Issue 2, 2011, Pages 337-344

  Pan, Yongmei ^a   Li, Linhao ^a   Kim, Gregory ^a   Ekins, Sean ^b,c   Wang, Hongbing ^a   Swaan, Peter W ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b Collaborations in Chemistry ^*  (United States)

^c RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLUTETHIMIDE; BECLOMETASONE; CEFOXITIN; CYTOCHROME P450 2B6; DIMETHYL SULFOXIDE; ESTRAMUSTINE; FINASTERIDE; FLUDROCORTISONE; FLUNISOLIDE; FLUTICASONE; FLUTICASONE PROPIONATE; LIGAND; LUCIFERASE; MEGESTROL; MEGESTROL ACETATE; MITOMYCIN; NIMODIPINE; NISOLDIPINE; PREGNANE X RECEPTOR; PRESCRIPTION DRUG; RIFAMPICIN; SALAZOSULFAPYRIDINE; SECOBARBITAL; TOBRAMYCIN; TRIAMCINOLONE;

ACCURACY; ARTICLE; BAYES THEOREM; CELL STRAIN HEPG2; CONTROLLED STUDY; DATA BASE; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; IN VITRO STUDY; PREDICTION; PRIORITY JOURNAL;

BAYES THEOREM; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HEP G2 CELLS; HUMANS; LIGANDS; LUCIFERASES; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; PRESCRIPTION DRUGS; PRINCIPAL COMPONENT ANALYSIS; RECEPTORS, STEROID; REPRODUCIBILITY OF RESULTS;

EID: 79251516763     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.035808     Document Type: Article

References (45)

1. Backman JT, Olkkola KT, and Neuvonen PJ (1996) Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 59:7-13.
2. Bhadhprasit W, Sakuma T, Hatakeyama N, Fuwa M, Kitajima K, and Nemoto N (2007) Involvement of glucocorticoid receptor and pregnane X receptor in the regulation of mouse CYP3A44 female-predominant expression by glucocorticoid hormone. Drug Metab Dispos 35:1880-1885.
3. Chang C, Bahadduri PM, Polli JE, Swaan PW, and Ekins S (2006) Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos 34:1976-1984.
4. Cheng J, Ma X, Krausz KW, Idle JR, and Gonzalez FJ (2009) Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 37:1611-1621.
5. Chiba M, Hensleigh M, and Lin JH (1997) Hepatic and intestinal metabolism of indinavir, an HIV protease inhibitor, in rat and human microsomes. Major role of CYP3A. Biochem Pharmacol 53:1187-1195.
6. Chrencik JE, Orans J, Moore LB, Xue Y, Peng L, Collins JL, Wisely GB, Lambert MH, Kliewer SA, and Redinbo MR (2005) Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin. Mol Endocrinol 19:1125-1134.
7. Crowston JG, Wang XY, Khaw PT, Zoellner H, and Healey PR (2006) Human serum reduces mitomycin-C cytotoxicity in human tenon's fibroblasts. Invest Ophthalmol Vis Sci 47:946-952.
8. di Masi A, De Marinis E, Ascenzi P, and Marino M (2009) Nuclear receptors CAR and PXR: molecular, functional, and biomedical aspects. Mol Aspects Med 30:297-343.
9. Drocourt L, Pascussi JM, Assenat E, Fabre JM, Maurel P, and Vilarem MJ (2001) Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos 29:1325-1331.
10. Ekins S, Kholodovych V, Ai N, Sinz M, Gal J, Gera L, Welsh WJ, Bachmann K, and Mani S (2008) Computational discovery of novel low micromolar human pregnane X receptor antagonists. Mol Pharmacol 74:662-672.
11. Ekins S, Kortagere S, Iyer M, Reschly EJ, Lill MA, Redinbo MR, and Krasowski MD (2009) Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol 5:e1000594.
12. Gao YD, Olson SH, Balkovec JM, Zhu Y, Royo I, Yabut J, Evers R, Tan EY, Tang W, Hartley DP, et al. (2007) Attenuating pregnane X receptor (PXR) activation: a molecular modelling approach. Xenobiotica 37:124-138.
13. Gunnarsson O, Andersson SB, and Johansson SA (1983) The hydrolysis of estramustine phosphate; in vitro studies. Eur J Drug Metab Pharmacokinet 8:395-402.
14. Ivanovic J, Jelena I, Nicastri E, Emanuele N, Ascenzi P, Paolo A, Bellagamba R, Rita B, De Marinis E, Elisabetta de M, et al. (2008) Therapeutic drug monitoring in the management of HIV-infected patients. Curr Med Chem 15:1925-1939.
15. Jain AN (2003) Surflex: fully automatic flexible molecular docking using a molecular similaritybased search engine. J Med Chem 46:499-511.
16. Jones G, Willett P, Glen RC, Leach AR, and Taylor R (1997) Development and validation of a genetic algorithm for flexible docking. J Mol Biol 267:727-748.
17. Jyrkkärinne J, Windshügel B, Rönkkö T, Tervo AJ, Küblbeck J, Lahtela-Kakkonen M, Sippl W, Poso A, and Honkakoski P (2008) Insights into ligand-elicited activation of human constitutive androstane receptor based on novel agonists and three-dimensional quantitative structure-activity relationship. J Med Chem 51:7181-7192.
18. Khandelwal A, Bahadduri PM, Chang C, Polli JE, Swaan PW, and Ekins S (2007) Computational models to assign biopharmaceutics drug disposition classification from molecular structure. Pharm Res 24:2249-2262.
19. Khandelwal A, Krasowski MD, Reschly EJ, Sinz MW, Swaan PW, and Ekins S (2008) Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol 21:1457-1467.
20. Krueger BA, Weil T, and Schneider G (2009) Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists. J Comput Aided Mol Des 23:869-881.
21. Lemaire G, de Sousa G, and Rahmani R (2004) A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem Pharmacol 68:2347-2358.
22. Ma X, Idle JR, and Gonzalez FJ (2008) The pregnane X receptor: from bench to bedside. Expert Opin Drug Metab Toxicol 4:895-908.
23. Maglich JM, Stoltz CM, Goodwin B, Hawkins-Brown D, Moore JT, and Kliewer SA (2002) Nuclear pregnane X receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification. Mol Pharmacol 62:638-646.
24. Messina A, Nannelli A, Fiorio R, Longo V, and Gervasi PG (2009) Expression and inducibility of CYP1A1, 1A2, 1B1 by β-naphthoflavone and CYP2B22, 3A22, 3A29, 3A46 by rifampicin in the respiratory and olfactory mucosa of pig. Toxicology 260:47-52.
25. Mulligan K, Zackin R, Von Roenn JH, Chesney MA, Egorin MJ, Sattler FR, Benson CA, Liu T, Umbleja T, Shriver S, et al. (2007) Testosterone supplementation of megestrol therapy does not enhance lean tissue accrual in men with human immunodeficiency virus-associated weight loss: a randomized, double-blind, placebo-controlled, multicenter trial. J Clin Endocrinol Metab 92:563-570.
26. Pagano G, Degan P, De Biase A, Iaccarino M, and Warnau M (2001) Diepoxybutane and mitomycin C toxicity is associated with the induction of oxidative DNA damage in sea urchin embryos. Hum Exp Toxicol 20:651-655.
27. Plant N (2007) The human cytochrome P450 sub-family: transcriptional regulation, interindividual variation and interaction networks. Biochim Biophys Acta 1770:478-488.
28. Rarey M, Kramer B, Lengauer T, and Klebe G (1996) A fast flexible docking method using an incremental construction algorithm. J Mol Biol 261:470-489.
29. Rogers D, Brown RD, and Hahn M (2005) Using extended-connectivity fingerprints with Laplacian-modified Bayesian analysis in high-throughput screening follow-up. J Biomol Screen 10:682-686.
30. Ruppert J, Welch W, and Jain AN (1997) Automatic identification and representation of protein binding sites for molecular docking. Protein Sci 6:524-533.
31. Stahl M (2000) Modifications of the scoring function in FlexX for virtual screening applications. Perspect Drug Discov Des 20:83-98.
32. Timsit YE and Negishi M (2007) CAR and PXR: the xenobiotic-sensing receptors. Steroids 72:231-246.
33. Tolson AH, Li H, Eddington ND, and Wang H (2009) Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos 37:1887-1894.
34. Ung CY, Li H, Yap CW, and Chen YZ (2007) In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol 71:158-168.
35. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M, and LeCluyse EL (2003) A novel distal enhancer module regulated by pregnane X receptor/constitutive androstane receptor is essential for the maximal induction of CYP2B6 gene expression. J Biol Chem 278:14146-14152.
36. Watkins RE, Davis-Searles PR, Lambert MH, and Redinbo MR (2003) Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol 331:815-828.
37. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, and Redinbo MR (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329-2333.
38. Welch W, Ruppert J, and Jain AN (1996) Hammerhead: fast, fully automated docking of flexible ligands to protein binding sites. Chem Biol 3:449-462.
39. Xia X, Maliski EG, Gallant P, and Rogers D (2004) Classification of kinase inhibitors using a Bayesian model. J Med Chem 47:4463-4470.
40. Xu RX, Lambert MH, Wisely BB, Warren EN, Weinert EE, Waitt GM, Williams JD, Collins JL, Moore LB, Willson TM, et al. (2004) A structural basis for constitutive activity in the human CAR/RXRα heterodimer. Mol Cell 16:919-928.
41. Xue Y, Moore LB, Orans J, Peng L, Bencharit S, Kliewer SA, and Redinbo MR (2007) Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol 21:1028-1038.
42. Yasuda K, Ranade A, Venkataramanan R, Strom S, Chupka J, Ekins S, Schuetz E, and Bachmann K (2008) A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos 36:1689-1697.
43. Zientek M, Stoner C, Ayscue R, Klug-McLeod J, Jiang Y, West M, Collins C, and Ekins S (2010) Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4 time-dependent inhibition. Chem Res Toxicol 23:664-676.
44. Zimmermann C, van Waterschoot RA, Harmsen S, Maier A, Gutmann H, and Schinkel AH (2009) PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci 36:565-571.
45. Zweig MH and Campbell G (1993) Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 39:561-577.